Alvotech (ALVO)

NGM – Real Time Price. Currency in USD

3.55

-0.04 (-1.11%)

At close: May 12, 2026, 4:00 PM EDT

3.54

-0.01 (-0.28%)

After-hours: May 12, 2026, 7:19 PM EDT

11.05.2026

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company's manufacturing facility in Reykjavik, Iceland. At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483.

08.05.2026

Alvotech (ALVO) Q1 2026 Earnings Call Transcript

07.05.2026

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.35 per share a year ago.

06.05.2026

Alvotech Q1 2026 Financial Results

Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational details and business update for Q1 2026 is available at: https://investors.alvotech.com/earnings-calendar under “Q1 2026 Earnings Call”. The supplemental document is provided solely for reference and is not part of this SEC Form 6 ‑ K.

24.04.2026

Alvotech to Report Financial Results for the First Quarter of 2026

REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close.

24.04.2026

Alvotech to Report Financial Results for the First Quarter of 2026

REYKJAVIK, ICELAND (April 24, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close.

10.04.2026

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers.

Videos

No Data

There is no data to display

Press releases

11.05.2026

Alvotech (ALVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alvotech (ALVO)

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech (ALVO) Q1 2026 Earnings Call Transcript

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech Q1 2026 Financial Results

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Videos

No Data

Press releases

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech (ALVO) Q1 2026 Earnings Call Transcript

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech Q1 2026 Financial Results

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Videos

No Data

Press releases

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Q1 2026 Financial Results

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report

Search stocks

Alvotech (ALVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alvotech (ALVO)

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech (ALVO) Q1 2026 Earnings Call Transcript

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech Q1 2026 Financial Results

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Videos

No Data

Press releases

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech (ALVO) Q1 2026 Earnings Call Transcript

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech Q1 2026 Financial Results

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Videos

No Data

Press releases

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Q1 2026 Financial Results

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report